RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:2 weeks: It’s all it took for Merck to get AAHi FGPstock - I think you've got things mixed up a bit. There can't be any launch of TLD-1433 sales in 2024 without accelerated approval. Assuming we treat all 100-120 patients by the end of 2023 we will have to wait another 450 days before applying to the FDA and HC for approval which will bring us to 2025. What you quoted below is from an older report by Dr. Uddin. Currently he does not project approval before 2026. Analysts get things wrong all the time. If we do get AA he will just change his analysis again and not lose a wink of sleep. FGPstock wrote:
Didn't say I was selling. Just trying to figure out why the person who knows more than all of us just pushed backed the revenue target 2 years
I don't need to be a pumper like you to invest in a stock. I look try to look at things objectively. You should give it a try.
He also expects 2022 ($907,000) and 2023 ($998,000) to come in below the $1 million mark in terms of revenue, but he forecasts 2024 to be a major year, with the forecasted launch of TLD-1433 sales expected to fuel a rise to $30.9 million in revenue, the start of a growth ramp that Uddin forecasts to reach $255 million by 2030, almost entirely fuelled by continued TLD-1433 sales.